Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1846 results
May 2021
-
Press release
Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program
Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus… -
Featured News
Novartis Hematology: Relentless Pursuit of a Cure
Novartis is committed to transforming the lives of people living with blood cancers and serious blood disorders. -
Press release
Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19
EMPATHY global multi-center Phase 2 - 3 study, recruiting patients with COVID-19 infection, aiming to prevent worsening symptoms and hospitalizationThe study plans to enroll 2100 patients, with 400… -
Pulse Update
Novartis receives FDA fast track designation for sabatolimab (MBG453) in myelodysplastic syndromes
-
Press release
Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer
Overall survival and radiographic PFS from phase III study of investigational radioligand therapy 177Lu-PSMA-617 VISION trial of patients with metastatic castration-resistant prostate cancer to be… -
Press release
Sandoz announces plans to further strengthen its antibiotics manufacturing setup in Europe
Sandoz to invest €150 million in new antibiotics manufacturing technology in Europe over next three to five years, to be optimally prepared for future needsKundl, Austria further strengthens… -
Press release
Novartis reaches milestone delivery of 1 billion courses of antimalarial treatment
Novartis has delivered 1 billion courses of antimalarial treatment, including 430 million pediatric treatments, largely at no profit since 1999With other innovations, the Novartis artemisinin-based… -
Press release
US Supreme Court denies Sandoz petition to review biosimilar Erelzi® (etanercept-szzs) case
Decision not to review Federal Circuit July 2020 ruling continues to prevent Sandoz launch of more affordable Erelzi treatment option for US patients Sandoz is disappointed US patients affected by… -
Featured News
World Asthma Day 2021
Understanding asthma: What are your misconceptions? This World Asthma Day find out more about asthma and challenge your misconceptions.
-
Story Access to Healthcare
Fighting MS through innovation
Investing in innovative treatments is vital to alleviate the suffering caused by multiple sclerosis (MS).
-
Press release
Sandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine
Sandoz to begin enrolling patients with neovascular age-related macular degeneration in MYLIGHT Phase lll confirmatory efficacy and safety study1Neovascular age-related macular degeneration accounts…